



Claims

1. A compound of formula (Ia, Ib, II, III or IV) wherein formula (Ia) is represented by:



- 5 a stereoisomeric form, a pharmaceutically acceptable salt, solvate or polymorph thereof comprising a mono- or di-substituted indole group; said compound is selected from the group wherein:
- R₁ is Cl, R₂ is H, R₃ is CH₃;
- R₁ is Cl, R₂ is OCH₃, R₃ is H;
- 10 R₁ is CH₃, R₂ is F or OCF₃ or H or OCH₂CH₃ and R₃ is H;
- R₁ and R₂ are connected forming a heterocycle of 5 members having one oxygen atom, R₃ is H;
- R₂ and R₃ are connected forming a heterocycle of 5 members having one oxygen atom, R₁ is H;
- 15 or wherein formula (Ib) is represented by:



- 20 a stereoisomeric form, a pharmaceutically acceptable salt, solvate or polymorph thereof comprising a mono- or di-substituted indole group; said compound is selected from the group wherein:
- R₄ is CH₃, R₅ is F, R₆ and R₇ are both H;
- R₄ is CH₃, R₅ is OCH₃, R₆ is H, R₇ is F;



R₄ is SF₅, R₅ = R₆ = R₇ are all H;

R₄ and R₅ are connected forming a heterocycle of 5 members having one oxygen atom, R₆ and R₇ are both H;


R₅ and R₆ are connected forming a heterocycle of 5 members having one oxygen atom, R₄ and R₇ are both H

5

and wherein compounds (II, III and IV) respectively are represented by:



10



















or a stereoisomeric form, a pharmaceutically acceptable salt, solvate or polymorph thereof.

15



2. A compound or its stereoisomeric form, a pharmaceutically acceptable salt, solvate or polymorph thereof according to claim 1 wherein said compound is selected from the group:


5





3. A pharmaceutical composition comprising a compound of formula (Ia, Ib, II, III or IV) or a stereoisomeric form, a pharmaceutically acceptable salt, solvate or polymorph thereof according to claim 1 or 2 together with one or more pharmaceutically acceptable excipients, diluents or carriers.
- 5
4. A compound of formula (Ia, Ib, II, III or IV) or a stereoisomeric form, a pharmaceutically acceptable salt, solvate or polymorph thereof according to claim 1 or a pharmaceutical composition according to claim 3 for use as a medicament.
- 10
5. A compound of formula (Ia, Ib, II, III or IV) or a stereoisomeric form, a pharmaceutically acceptable salt, solvate or polymorph thereof according to claim 1 or a pharmaceutical composition according to claim 3 for use in the treatment of dengue.
- 15
6. A use of a compound as represented by any of the structural formula from claims 1-5, a stereoisomeric form, a pharmaceutically acceptable salt, solvate or polymorph thereof comprising a mono- or di-substituted indole group for inhibiting the replication of dengue virus(es) in a biological sample or patient.
- 20
7. The use of a compound according to claim 6 further comprising co-administering an additional therapeutic agent.
8. The use of claim 7 wherein said additional therapeutic agent is selected from an antiviral agent or dengue vaccine, or both.
- 25
9. The compound as claimed in claim 1 wherein the compound is selected from





or a pharmaceutically acceptable salt, solvate or polymorph thereof.

10. A pharmaceutical composition comprising a compound according to claim 9,
 5 a pharmaceutically acceptable salt, solvate or polymorph thereof together
 with one or more pharmaceutically acceptable excipients, diluents or carriers.

11. A compound according to claim 9, a pharmaceutically acceptable salt, solvate or polymorph thereof or a pharmaceutical composition according to claim 10 for use as a medicament.
- 5 12. A compound according to claim 9, a pharmaceutically acceptable salt, solvate or polymorph thereof or a pharmaceutical composition according to claim 10 for use in the treatment of dengue.
- 10 13. A use of a compound as represented by any of the structural formula from claim 9, a pharmaceutically acceptable salt, solvate or polymorph thereof comprising a mono- or di-substituted indole group for inhibiting the replication of dengue virus(es) in a biological sample or patient.
- 15 14. The use according to claim 13 which use further comprises co-administering an additional therapeutic agent.
- 15 15. The use according to claim 14 wherein said additional therapeutic agent is selected from an antiviral agent or dengue vaccine, or both.